Interleukin-4 - Amgen/Sanofi Winthrop

Drug Profile

Interleukin-4 - Amgen/Sanofi Winthrop

Latest Information Update: 19 Apr 1996

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Sanofi Winthrop
  • Class Interleukins
  • Mechanism of Action B cell stimulants; Immunosuppressants; Interleukin 4 receptor agonists; Mast cell stabilisers; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Graft-versus-host disease; Immunodeficiency disorders

Most Recent Events

  • 19 Apr 1996 Discontinued-Unspecified phase for Immunodeficiency disorders in USA (Unknown route)
  • 13 Dec 1995 Discontinued-Preclinical for Graft-versus-host disease in USA (Unknown route)
  • 28 Sep 1995 Discontinued-II for Cancer in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top